Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy.
Interleukin-2 (IL-2) increases circulating CD4(+) lymphocytes in patients infected with human immunodeficiency virus-1. We studied Epstein-Barr virus (EBV) dynamics in 40 patients treated with antiretroviral therapy (ART) plus different IL-2 regimens. EBV-DNA tended to increase in both peripheral blood cells and plasma after continous infusion followed by intermittent subcutaneous high-dose IL-2, while EBV-DNA decreased in cells (p=0.0078) and disappeared in plasma after intermittent subcutaneous low-dose IL-2. Over 12 months, the dynamics of EBV differed between the two groups both in cells (p=0.0184) and plasma (p=0.0114). Thus, as a function of dose, IL-2 therapy may significantly affect the dynamics of EBV infection.
Burighel
Nicoletta
N
Department of Oncology and Surgical Sciences, Section of Oncology, AIDS Reference Center, University of Padova, Italy.
Ghezzi
Silvia
S
Nozza
Silvia
S
Del Bianco
Paola
P
Lazzarin
Adriano
A
Tambussi
Giuseppe
G
Poli
Guido
G
De Rossi
Anita
A
D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D004279:DNA, Viral / Q000097:blood; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy*; D015497:HIV-1; D004854:Herpesvirus 4, Human; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage; D019562:Viral Load
D044966:Anti-Retroviral Agents; D004279:DNA, Viral; D007376:Interleukin-2